stars 1 stars 2 stars 3

OncoTherics is a new pharmaceutical company, focusing on the development of novel hypoxia-activated pro-drugs for the treatment of a wide range of cancers... The company was formed as a spin-out from BioStatus, to progress a novel small molecule, code-named OCT1002. The company is at an early stage but the patented technology has a unique history allowing a more rapid than usual progression through the clinical trial process. For further information, please contact us using the contact form provided on this site ...

OncoTherics Questions

The OncoTherics annual revenue was $4 million in 2026.

Paul Smith is the CSO and Director of OncoTherics.

2 people are employed at OncoTherics.

The NAICS codes for OncoTherics are [541, 54, 541714, 54171, 5417].

The SIC codes for OncoTherics are [873, 87].

Top OncoTherics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users